Circular Genomics Expands Advisory Board with Leading Alzheimer's Researchers to Enhance Neurology Advances

Circular Genomics Strengthens Its Scientific Advisory Board

Circular Genomics, a prominent player in the field of circular RNA biomarkers for precision neurology and psychiatry, has recently announced a strategic enhancement to its Scientific Advisory Board (SAB). This development comes in light of the appointments of two highly esteemed experts in Alzheimer's disease research: Dr. Michael Weiner and Dr. Timothy Hohman. These experts bring extensive expertise and a wealth of knowledge, significantly bolstering Circular Genomics’ mission to advance circular RNA-based diagnostic tests for Alzheimer's and other neurological disorders.

The New Additions to the Board

Dr. Michael Weiner, an esteemed figure in clinical Alzheimer's disease research, serves as a Professor Emeritus at the University of California, San Francisco (UCSF). He leads the groundbreaking Alzheimer's Disease Neuroimaging Initiative (ADNI), recognized as the largest observational study focused on Alzheimer's disease globally. His contributions span decades, aiming to optimize diagnostic methods using advanced imaging technologies, such as MRI and PET, alongside blood-based biomarkers. Additionally, Dr. Weiner initiated the Brain Health Registry, an innovative platform aimed at accelerating treatment development through collaborative research efforts.

Conversely, Dr. Timothy Hohman, a cognitive neuroscientist and computational geneticist, holds the position of Professor of Neurology at the Vanderbilt University Medical Center. With a PhD in Neuroscience, Dr. Hohman is renowned for his pioneering research that leverages computational approaches to discover new risk factors and resilience markers for Alzheimer's disease. He is at the forefront of the Vanderbilt Memory Alzheimer's Center, leading initiatives that bridge various data types to enhance precision medicine practices within neurology.

A Transformative Era for Circular Genomics

“This appointment marks a transformative moment for Circular Genomics,” stated Nikolaos Mellios, MD, PhD, Chief Scientific Officer and co-founder of the organization. “Dr. Weiner's and Dr. Hohman's combined knowledge in significant clinical trials, neuroimaging, and computational genomics are invaluable assets in our pursuit to validate and commercialize our advanced circRNA biomarkers for Alzheimer's disease and other neurological disorders.”

The addition of these two experts further strengthens an already distinguished advisory board at Circular Genomics, which includes several professionals such as Roy Perlis, MD, and Madhukar Trivedi, MD. Together, this team brings diverse strengths in neurology, psychiatry, and precision medicine, showcasing Circular Genomics' commitment to leading innovation in the treatment and understanding of neurological diseases.

About Circular Genomics

Established as a leader in the development of circular RNA-based precision medicine tools, Circular Genomics is dedicated to transforming the standard of care for early diagnosis of neurological and psychiatric diseases such as Alzheimer's disease, Parkinson's disease, and major depressive disorder. Their innovative approach integrates cutting-edge technologies and exclusive licenses in circular RNA, delivering tailored patient management pathways for more effective care.